NEUP vs AHT Comparison

Neuphoria Therapeutics Inc is a clinical-stage biotechnology company focused on therapies for serious central nervous system disorders. Its lead product candidate, BNC210, is an oral, proprietary, selective negative allosteric modulator of the alpha7 nicotinic acetylcholine receptor. The company has discontinued development of BNC210 for social anxiety disorder, while its BNC210 program for post-traumatic stress disorder is currently paused and no active clinical trial is underway. The company operates through a single operating and reporting segment focused on the discovery and development of allosteric ion-channel modulators for serious CNS disorders with high unmet medical need.

Ashford Hospitality Trust Inc is a real estate investment trust (REIT) operating in the hotel lodging industry. The company's portfolio consists of upscale and upper upscale full-service hotels, with its investment focused on acquiring and investing in upper upscale full-service hotels in the United States that have revenue per available room (RevPAR) generally less than twice the U.S. national average, through direct real estate ownership as well as equity and debt investments. Its hotel properties are mainly branded under internationally recognized names such as Hilton, Hyatt, Marriott, and InterContinental Hotels Group. It operates through a single reportable business segment, direct hotel investments, which involves owning hotel properties through acquisitions or new development.